A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes

por Platzbecker, U, Symeonidis, A, Oliva, E N, Goede, J S, Delforge, M, Mayer, J, Slama, B, Badre, S, Gasal, E, Mehta, B, Franklin, J
Publicado 2017

Treatment with Hizentra in patients with primary and secondary immunodeficiencies: a real-life, non-interventional trial

por Viallard, J. F., Agape, P., Barlogis, V., Cozon, G., Faure, C., Fouyssac, F., Gaud, C., Gourin, M. P., Hamidou, M., Hoarau, C., Husseini, F., Ojeda-Uribe, M., Pavic, M., Pellier, I., Perlat, A., Schleinitz, N., Slama, B.
Publicado 2016

P872: DEL(1P32) REMAINS A POWERFUL PROGNOSTIC FACTOR IN A LARGE COHORT OF NDMM PATIENTS: AN UPDATE

por Schavgoulidze, A., Perrot, A., Cazaubiel, T., Leleu, X., Manier, S., Buisson, L., Maheo, S., Do Souto Ferreira, L., Lannes, R., Pavageau, L., Hulin, C., Marolleau, J.-P., Voillat, L., Belhadj, K., Divoux, M., Slama, B., Brechignac, S., Macro, M., Stoppa, A.-M., Sanhes, L., Orsini-Piocelle, F., Fontan, J., Chretien, M.-L., Demarquette, H., Mohty, M., Avet-Loiseau, H., Corre, J.
Publicado 2022

P1133: SUB-CUTANEOUS RITUXIMAB INDUCTION FOLLOWED BY SHORT RITUXIMAB MAINTENANCE IMPROVES PFS IN PATIENTS WITH LOW-TUMOR BURDEN FOLLICULAR LYMPHOMA. FINAL RESULTS OF FLIRT PHASE II...

por Cartron, G., Bachy, E., Tilly, H., Daguindau, N., Pica, G.-M., Bijou, F., Mounier, C., Clavert, A. M., Damaj, G. L., Slama, B., Casasnovas, O., Houot, R., Bouabdallah, K., Sibon, D., Fitoussi, O., Morineau, N., Herbaux, C., Gastinne, T., Fornecker, L.-M., Haioun, C., Launay, V., Araujo, C., Benbrahim, O., Sanhes, L., Gressin, R., Gonzalez, H., Morschhauser, F., Xerri, L., Tarte, K., Pranger, D.
Publicado 2022